Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An adaptive Phase 3 program of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab, similar to the Precision Promise study

Next Previous
Trial Profile

An adaptive Phase 3 program of pelareorep, gemcitabine, nab-paclitaxel, and atezolizumab, similar to the Precision Promise study

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pelareorep (Primary) ; Atezolizumab; Gemcitabine; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 19 Nov 2025 According to an Oncolytics Therapeutics media release, the company is now completing the administrative activities necessary to initiate the study, including finalizing the protocol, generation of supporting documents, and site selection. The company also plan to announce the lead principal investigator once these preparations are complete.
  • 19 Nov 2025 According to an Oncolytics Therapeutics media release, the company announced alignment with the U.S. Food and Drug Administration (FDA) regarding the design of this pivotal study. The Company and the FDA completed a recent Type C meeting and have agreed on the key elements of the study.
  • 29 Sep 2025 According to an Oncolytics Therapeutics media release, an interim efficacy analysis will be incorporated to enable early assessment of potential clinical benefit.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top